Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Front Immunol ; 11: 345, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32194563

RESUMO

The palladacycle complex DPPE 1.2 was previously shown to inhibit Leishmania (Leishmania) amazonensis infection in vitro and in vivo. The present study aimed to evaluate the effect of DPPE 1.2 associated with a recombinant cysteine proteinase, rLdccys1, and the adjuvant Propionibacterium acnes on L. (L.) amazonensis infection in two mouse strains, BALB/c, and C57BL/6. Treatment with this association potentiated the leishmanicidal effect of DPPE 1.2 resulting in a reduction of parasite load in both strains of mice which was higher compared to that found in groups treated with either DPPE 1.2 alone or associated with P. acnes or rLdccys1. The reduction of parasite load in both mice strains was followed by immunomodulation mediated by an increase of memory CD4+ and CD8+ T lymphocytes, IFN-γ levels and reduction of active TGF-ß in treated animals. No infection relapse was observed 1 month after the end of treatment in mice which received DPPE 1.2 associated with rLdccys1 or rLdccys1 plus P. acnes in comparison to that exhibited by animals treated with DPPE 1.2 alone. Evaluation of serum levels of AST, ALT, urea, and creatinine showed no alterations among treated groups, indicating that this treatment schedule did not induce hepato or nephrotoxicity. These data indicate the potential use of this association as a therapeutic alternative for cutaneous leishmaniasis caused by L. (L) amazonensis.


Assuntos
Antiprotozoários/uso terapêutico , Cisteína Endopeptidases/uso terapêutico , Imunoterapia/métodos , Leishmaniose Cutânea/tratamento farmacológico , Propionibacterium acnes , Proteínas de Protozoários/uso terapêutico , Animais , Antiprotozoários/administração & dosagem , Antiprotozoários/toxicidade , Terapia Combinada , Cisteína Endopeptidases/administração & dosagem , Cisteína Endopeptidases/imunologia , Cisteína Endopeptidases/toxicidade , Avaliação Pré-Clínica de Medicamentos , Feminino , Memória Imunológica , Interferon gama/metabolismo , Leishmania mexicana , Leishmaniose Cutânea/imunologia , Linfonodos/imunologia , Ativação Linfocitária/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Proteínas de Protozoários/administração & dosagem , Proteínas de Protozoários/imunologia , Proteínas de Protozoários/toxicidade , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/imunologia , Proteínas Recombinantes/uso terapêutico , Proteínas Recombinantes/toxicidade , Subpopulações de Linfócitos T/imunologia , Fator de Crescimento Transformador beta/metabolismo
2.
J Med Food ; 14(6): 557-62, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21554130

RESUMO

The infections by protozoans of the genus Leishmania are a major worldwide health problem, with high endemicity in developing countries. The drugs of choice for the treatment of leishmaniasis are the pentavalent antimonials, which cause renal and cardiac toxicity. As part of a search for new drugs against leishmaniasis, we evaluated the in vitro Leishmania protease inhibition activity of extracts (hexanic, ethyl-acetate, and ethanolic) and fukugetin, a bioflavonoid purified from the ethyl-acetate extract of the pericarp of the fruit of Garcinia brasiliensis, a tree native to Brazilian forests. The isolated compound was characterized by using spectral analyses with nuclear magnetic resonance, mass spectroscopy, ultraviolet, and infrared techniques. The ethyl-acetate extract and the compound fukugetin showed significant activity as inhibitors of Leishmania's proteases, with mean (±SD) IC(50) (50% inhibition concentration of protease activity) values of 15.0±1.3 µg/mL and 3.2±0.5 µM/mL, respectively, characterizing a bioguided assay. In addition, this isolated compound showed no activity against promastigote and amastigote forms of L. (L.) amazonensis and mammalian cells. These results suggest that fukugetin is a potent protease inhibitor of L. (L.) amazonensis and does not cause toxicity in mammalian or Leishmania cells in vitro. This study provides new perspectives on the development of novel drugs that have leishmanicidal activity obtained from natural products and that target the parasite's proteases.


Assuntos
Antiprotozoários/farmacologia , Garcinia/química , Leishmania/efeitos dos fármacos , Leishmania/enzimologia , Extratos Vegetais/farmacologia , Inibidores de Proteases/farmacologia , Proteínas de Protozoários/antagonistas & inibidores , Animais , Brasil , Frutas/química , Humanos , Concentração Inibidora 50 , Leishmaniose/parasitologia , Peptídeo Hidrolases/metabolismo , Proteínas de Protozoários/metabolismo , Ratos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA